Literature DB >> 36074278

Predictors of response for percutaneous balloon compression for the treatment of recurrent trigeminal neuralgia following surgical procedures: a retrospective study.

Lu Liu1, Zhe Sun1, Yan Zhang1, Guofeng Ma1, Fang Luo2.   

Abstract

Recurrent trigeminal neuralgia (TN) after surgical procedures can be rather difficult to treat, and standardized treatment measures are not available yet. It is unclear whether percutaneous balloon compression (PBC) can be used as the preferred surgical treatment for postoperative recurrent TN. To determine the efficacy of PBC and identify the predictors of response of PBC for the treatment of recurrent TN following TN-related surgeries, we retrospectively collected and analyzed the data of patients with recurrent TN following surgical treatments who underwent PBC under three-dimensional computed tomography (3D-CT) guidance at the Department of Pain Management of Beijing Tiantan Hospital, Capital Medical University from January 2018 to January 2022. We found, within 1 month after PBC, that the total efficacy of PBC on recurrent TN following TN-related surgeries was 86.7%. Based on the effectiveness of PBC 1 month postoperatively, patients were divided into the effective group (130, 86.7%) and the ineffective group (20, 13.3%). Fourteen (10.8%) patients in the effective group had undergone RFT before, which was significantly lower than that in the ineffective group (6, 30%, p = 0.02). Multivariate logistic regression analysis showed that previous RFT alone (OR = 0.20, 95%CI 0.06-0.66, P = 0.01) was an independent predictor of the negative response of PBC. Thus, PBC was found to be a moderately effective and safe treatment for recurrent TN after TN-related surgery. However, previous RFT procedures may predict a slightly worse outcome after PBC.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Efficacy; Percutaneous balloon compression; Prediction; Recurrent trigeminal neuralgia

Mesh:

Year:  2022        PMID: 36074278     DOI: 10.1007/s10143-022-01852-x

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   2.800


  14 in total

1.  The psychosocial impact of orofacial pain in trigeminal neuralgia patients: a systematic review.

Authors:  L N Melek; M Devine; T Renton
Journal:  Int J Oral Maxillofac Surg       Date:  2018-03-08       Impact factor: 2.789

2.  Some examples of balloon technology in neurosurgery.

Authors:  S Mullan; E E Duda; N J Patronas
Journal:  J Neurosurg       Date:  1980-03       Impact factor: 5.115

3.  Repeated percutaneous balloon compression for recurrent trigeminal neuralgia: a long-term study.

Authors:  Jyi-Feng Chen; Po-Hsun Tu; Shih-Tseng Lee
Journal:  World Neurosurg       Date:  2011-11-07       Impact factor: 2.104

4.  The Analysis of Percutaneous Balloon Compression on Efficacy and Negative Emotion in the Treatment of Recurrent Trigeminal Neuralgia After Surgical Procedures.

Authors:  Xiaochong Fan; Fuxing Xu; Huan Ren; Zhongyuan Lu; Huilian Bu; Letian Ma; Cunlong Kong; Tao Wang
Journal:  Pain Physician       Date:  2021-12       Impact factor: 4.965

5.  Percutaneous balloon compression for persistent or recurrent trigeminal neuralgia after microvascular decompression: personal experience of 28 patients.

Authors:  Wu Xu; Chengrong Jiang; Chen Yu; Weibang Liang
Journal:  Acta Neurol Belg       Date:  2017-11-06       Impact factor: 2.396

6.  Percutaneous microcompression of the trigeminal ganglion for trigeminal neuralgia.

Authors:  S Mullan; T Lichtor
Journal:  J Neurosurg       Date:  1983-12       Impact factor: 5.115

Review 7.  Various surgical modalities for trigeminal neuralgia: literature study of respective long-term outcomes.

Authors:  M Tatli; O Satici; Y Kanpolat; M Sindou
Journal:  Acta Neurochir (Wien)       Date:  2008-01-14       Impact factor: 2.216

8.  Trigeminal neuralgia: An overview from pathophysiology to pharmacological treatments.

Authors:  Eder Gambeta; Juliana G Chichorro; Gerald W. Zamponi
Journal:  Mol Pain       Date:  2020 Jan-Dec       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.